Sageworth Trust Company of South Dakota’s Cytokinetics CYTK Stock Holding History

Sageworth Trust Company of South Dakota’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-141	Closed	-$4.96K	–	79
2023 Q1	$4.96K	Hold	141	–	–	0.01%	145
2022 Q4	$6K	Hold	141	–	–	0.01%	145
2022 Q3	$7K	Sell	141 -37	-21%	-$1.78K	0.02%	117
2022 Q2	$7K	Sell	178 -33	-16%	-$1.33K	0.01%	180
2022 Q1	$8K	Hold	211	–	–	0.02%	220
2021 Q4	$10K	Buy	+211	New	+$8.14K	0.02%	377

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Sageworth Trust Company of South Dakota's CYTK Position: Q2 2023 in Review

Sageworth Trust Company of South Dakota sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 141 shares — an estimated $4.96K sold.

Sageworth Trust Company of South Dakota first reported a position in CYTK in Q4 2021 and held it in 6 quarters. The position peaked at $10K in Q4 2021. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

Sageworth Trust Company of South Dakota reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
Sageworth Trust Company of South Dakota sold 141 Cytokinetics shares in Q2 2023, an estimated $4.96K.
Sageworth Trust Company of South Dakota first reported a position in Cytokinetics in Q4 2021 and held it in 6 quarters.
Sageworth Trust Company of South Dakota's Cytokinetics position peaked at $10K in Q4 2021.
253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Sageworth Trust Company of South Dakota's 13F filing for Q2 2023, filed 3 Aug 2023.